基本信息
views: 0
![](https://originalfileserver.aminer.cn/sys/aminer/icon/show-trajectory.png)
Bio
Dr. Ratner is an Assistant Professor and Director of the Laboratory of Neurotoxicology at the Boston University Chobanian & Avedisian School of Medicine. She is Board Certified in Toxicology by the American Board of Toxicology. Dr. Ratner earned her doctoral degree in Behavioral Neuroscience from the Boston University Chobanian & Avedisian School of Medicine where she trained in the Department of Neurology at under the supervision of Drs. Robert G. Feldman, MD and Raymon Durso, MD. During her doctoral training, she was an active member of the the Environmental and Occupational Neurology Program. Dr. Ratner's dissertation research which revealed a younger age at onset of sporadic Parkinson's disease among subjects exposed to metals such as manganese and pesticides has been replicated by other investigators demonstrating the enduring importance as well as the rigor and reproducibility of her research (see Ratner et al., 2015 and Gamache et al., 2019).
Dr. Ratner subsequently completed a three year National Institute on Aging funded Post-Doctoral Fellowship in the Biochemistry of Aging under the supervision of Dr. David H. Farb in the Department of Pharmacology and Experimental Therapeutics at the Boston University Chobanian & Avedisian School of Medicine. Her postdoctoral training has provided Dr. Ratner with the additional expertise necessary to use preclinical animal models combined with in vivo electrophysiological techniques to effectively investigate how chemical exposures modulate neural network activity in vivo.
Her training at the bench and bedside has provided Dr. Ratner with genuine translational research experience in clinical as well as preclinical neuroscience and neurotoxicology. This unique combination of experience enables Dr. Ratner to effectively evaluate how chemicals modify neurological function and the progression of neurodegenerative disease in humans and animal models. The translational relevance of Dr. Ratner's research is reflected in the Approximate Potential to Translate aspect of the iCite scores of her publications.
Dr. Ratner's research focuses on clinical and preclinical investigations of how chemicals alter neurological function in healthy subjects and those with age-related neurodegenerative diseases. She and her clinical colleagues are exploring the use of serum exosomal alpha synuclein levels as a biomarker for differentiating young onset Parkinson's disease from parkinsonism in welders exposed to manganese (see Rutchik and Ratner, 2019). Her preclinical research employs basic behavioral and in vivo electrophysiological methods to investigate the effects of systemically administered chemicals on hippocampal neural network activity in animal models of neurodegenerative disease. This highly translational approach is well-suited for target-based as well as repurposing studies of drug-induced changes in both single unit activity and local field potentials. Dr. Ratner and her colleagues demonstrated that co-administration of low doses of the FDA approved anti-epileptic drugs levetiracetam and valproic acid improves aspects of place cell firing dynamics including increasing spatial information content in aged rats (Robitsek et al, Hippocampus, 2015) suggesting that the specificity with which, not just the rate at which, a neuron fires plays an important role in learning and memory function. Dr. Ratner and her colleagues (Ratner et al., Heliyon 2021) subsequently demonstrated that pharmacologically decreasing tonic inhibition in wild type rats increases place cell firing rates without abolishing place cell remapping while at the same time increasing the amplitude of sharp wave ripples implicated in memory consolidation. They also demonstrated that the observed augmentation of ripple amplitude in wild type rats is not seen in TgF344-AD rats implicating disrupted tonic inhibition in the early stages of AD. Her research using in vivo electrophysiology to measure dose-dependent changes in neural network activity (Ratner et al., Heliyon 2021) has been instrumental in advancing the applied use of this technology in preclinical neurotoxicology and drug discovery (Ratner and Farb, Front Toxicol, 2022).
Dr. Ratner is a Fellow of the Royal Society of Medicine. She is also a member of the American Academy of Clinical Toxicology, American Academy of Neurology, American Psychological Association and the Society of Toxicology. She serves on the Editorial Boards of Toxicology Communications and Frontiers in Toxicology and as a reviewer for several other professional medical and scientific journals including: Neurology, Toxicology, Clinical Toxicology, and BMC Pharmacology and Toxicology. In addition, Dr. Ratner has served as a scientific advisor, on the role of occupational exposures to chemicals in Parkinson's disease, to the Workplace Safety Insurance Board of Ontario, Canada. Dr. Ratner is also the Director of Research at Different Brains, Inc.
Research Interests
Papers共 31 篇Author StatisticsCo-AuthorSimilar Experts
By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Pharmacological reviewsno. 2 (2024): 251-266
crossref(2024)
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2023)
Neuroimmunology Reports (2022): 100140-100140
Frontiers in toxicology (2022): 836427
Advances in Neurotoxicology (2022)
Advances in NeurotoxicologyOccupational Neurotoxicologypp.47-75, (2022)
Load More
Author Statistics
Co-Author
Co-Institution
D-Core
- 合作者
- 学生
- 导师
Data Disclaimer
The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn